Fig. 1 · Structure

Documents & Downloads

Phlorizin (Phloridzin)

Cat. No. A10724 CAS 60-81-1

SGLT1/SGLT2 inhibitor

Phlorizin is a competitive inhibitor of SGLT1 and SGLT2; this reduces renal glucose transport, lowering the amount of glucose in the blood.

In Stock

Publications for Phlorizin

1 publication citing this product

  1. Subramaniam M, .et al. , Am J Physiol Regul Integr Comp Physiol, 2019, Nov 20 PMID: 31746628

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Phlorizin reversibly inhibits human SGLT1- and SGLT2-mediated glucose transport. In transfected HEK293T cells, estimated Ki values were 140 ± 15 nM for hSGLT1 and 11 ± 0.9 nM for hSGLT2 (means ± SE). These estimates used a competitive-inhibition model; slower recovery after washout accompanied the higher apparent affinity for hSGLT2. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
SGLT1  
SGLT2  

Cellular Effect

Cell Line Activity Value Description Reference
CHO EC50 108 nM Inhibition of human SGLT2 expressed in CHO cells assessed as sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting [PMID: 21128592]
CHO IC50 16 nM Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]AMG uptake after 45 mins [PMID: 21873071]
CHO IC50 16.4 nM Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins [PMID: 22889351]
CHO IC50 185 nM Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins [PMID: 22889351]
CHO IC50 190 nM Inhibition of human SGLT1 expressed in CHO cells assessed as [14C]AMG uptake after 45 mins [PMID: 21873071]
CHO EC50 197.4 nM Inhibition of human SGLT1 expressed in CHO cells assessed as sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting [PMID: 21128592]
CHO IC50 752 nM Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]alpha-methyl-D-glucopyranoside uptake by fluorescence polarization assay [PMID: 18755586]
CHO-K1 EC50 0.077 μM Inhibition of human SGLT2 expressed in CHO-K1 cells assessed as inhibition of [14C]-AMG uptake up to 120 mins by scintillation counting method [PMID: 24071445]
CHO-K1 EC50 0.12 μM Inhibition of human SGLT1 expressed in CHO-K1 cells assessed as inhibition of [14C]-AMG uptake up to 120 mins by scintillation counting method [PMID: 24071445]
CHO-K1 EC50 123 nM Inhibition of human SGLT2 expressed in CHO-K1 cells assessed as reduction in [14C]AMG uptake after 120 mins by scintillation counting method [PMID: 27075813]
CHO-K1 EC50 153 nM Inhibition of human SGLT1 expressed in CHO-K1 cells assessed as reduction in [14C]AMG uptake after 120 mins by scintillation counting method [PMID: 27075813]
CHO-K1 IC50 16 nM Inhibition of human SGLT2 expressed in CHO-K1 cells by [14C]AMG uptake assay [PMID: 22652255]
CHO-K1 IC50 190 nM Inhibition of human SGLT1 expressed in CHO-K1 cells by [14C]AMG uptake assay [PMID: 22652255]
COS-1 IC50 0.1 mM Inhibition of alpha-D-[U-14C]glucopyranoside uptake at human SGLT2 expressed in african green monkey COS1 cells after 30 mins by liquid scintillation counting [PMID: 20189404]
COS-1 IC50 0.2 mM Inhibition of alpha-D-[U-14C]glucopyranoside uptake at human SGLT1 expressed in african green monkey COS1 cells after 30 mins by liquid scintillation counting [PMID: 20189404]
COS-7 IC50 > 1000 μM Inhibition of human CNT2 expressed in COS7 cells assessed as reduction in sodium-dependent [14C]-inosine uptake in presence of Na+ by liquid scintillation counting method [PMID: 25815140]
HEK293 IC50 0.0673 μM Inhibition of human SGLT2 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay [PMID: 28098449]
HEK293 IC50 0.499 μM Inhibition of human SGLT1 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay [PMID: 28098449]
HEK293 IC50 58.6 nM Inhibition of SGLT2 (unknown origin) expressed in HEK293 cells using 2-NBDG as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by nonradioactive fluorescence glucose uptake assay [PMID: 24556379]

19 records · Scroll to view more

Phlorizin (Phloridzin) Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Phlorizin (Phloridzin) from 2 published references. In vitro models include hSGLT1-transfected, hSGLT2-transfected and untransfected HEK293T cells.

Phlorizin (Phloridzin) In Vitro Studies

In HEK293T cells expressing human SGLT1 or SGLT2, 100 μM phlorizin reduced αMDG uptake to background during a 40-minute assay at 37°C. Uptake in untransfected cells was not significantly affected, supporting transporter-associated inhibition in this assay. [1]

Reversible inhibition of human SGLT1 and SGLT2 currents

Cell-based study · HEK293T cells transiently expressing hSGLT1 or hSGLT2; whole-cell patch clamp at 37°C and −60 mV [1]

Extracellular phlorizin inhibited both human transporters. Ki was estimated from concentration-dependent current inhibition near the glucose K0.5 under a competitive-inhibition assumption. Washout showed slower recovery for hSGLT2. Direct association kinetics could not be resolved because of solution-change speed.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of glucose-induced currentKi hSGLT2: 11 ± 0.9 nM; hSGLT1: 140 ± 15 nM (means ± SE; n ≥ 3 cells)[1]
Recovery of glucose current after external phlorizin removalt1/2,Off hSGLT2: 24 ± 3 s; hSGLT1: 4 ± 0.5 s (means ± SE; n ≥ 3 cells)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Varied extracellular phlorizin for Ki estimation; 1 μM for Figure 7 wash-in/washout records
Exposure duration
Acute perfusion and washout; no fixed exposure interval given for Ki estimation
Method
Whole-cell glucose-induced current recording. Ki estimation used 5 mM glucose for hSGLT2 and 2 mM for hSGLT1; Figure 7 time courses used 100 mM and 2 mM glucose, respectively.
Vehicle
Extracellular recording buffer; compound stock solvent not specified in cited methods
Co-treatment
Glucose is the transported substrate, not a second inhibitor.
Reported limits
Compound-specific purity, lot and hydration state are not specified in Reagents; total exposure time for each concentration is not specified in the cited inhibition methods.
Methods and source locations

Compound reported in the paper: Phlorizin (Phloridzin); Compound label in the paper: Phlorizin

Human transporter assays using paper-tested material; reported assay constants are model-dependent.

Materials and Methods: Whole cell patch-clamp recordings; Phlorizin inhibition, Eqs. 6–8 (with corrigendum); Results: Phlorizin inhibition; Table 1; Figure 7

Inhibition of glucose-induced current: Estimated from IC50 near glucose K0.5, assuming competitive inhibition; 37°C, −60 mV. These are assay constants, not treatment doses. — Table 1, Ki phlorizin row and footnote; Methods Eq. 6; Results: Phlorizin inhibition

Recovery of glucose current after external phlorizin removal: Single-exponential fits to washout recovery. Figure 7 individual traces show 29 s and 3.8 s, distinct from Table 1 group means. — Table 1, t1/2,Off phlorizin row and footnote; Figure 7 and caption

Phlorizin-sensitive cellular αMDG uptake

Cell-based study · hSGLT1-transfected, hSGLT2-transfected and untransfected HEK293T cells [1]

At 100 μM, phlorizin reduced transporter-associated tracer uptake to background. It did not significantly change uptake in untransfected cells. This high-concentration functional control does not define an IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cellular αMDG uptake with versus without phlorizinFunctional inhibition and control comparison Transfected-cell uptake reduced to background (P < 0.05); untransfected-cell effect not significant (P > 0.05); n = 3 wells per bar, ± SE[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM phlorizin with 50 μM [14C]-α-methyl-D-glucopyranoside (αMDG)
Exposure duration
40 min at 37°C; uptake measured 2 days after transfection
Method
Radiotracer uptake and liquid scintillation counting; uptake expressed as pmol/min/well
Vehicle
Glucose-free PBS; compound stock solvent not specified
Co-treatment
No second inhibitor in the selected experiment.
Reported limits
Compound-specific purity, hydration state and stock solvent are not specified in the cited methods.
Methods and source locations

Compound reported in the paper: Phlorizin (Phloridzin); Compound label in the paper: Phlorizin

Human transporter assays using paper-tested material; reported assay constants are model-dependent.

Materials and Methods: Radioactive tracer uptakes; Results: Radioactive tracer uptakes; Figure 1 and caption

Cellular αMDG uptake with versus without phlorizin: Figure 1 qualitative group comparisons; no exact uptake values read from bar heights. — Figure 1 image and caption; Results: Radioactive tracer uptakes

Phlorizin (Phloridzin) In Vivo Studies

In male muscle-specific GLUT4 knockout mice, chronic phloridzin delivery at 0.7 mg/day from 12 to 20 weeks of age brought basal glucose close to control levels and preserved hepatic insulin responsiveness. Whole-body and skeletal-muscle insulin-stimulated glucose uptake nevertheless remained substantially below control, showing that correction of hyperglycemia did not remove the primary muscle defect in this model. [2]

Chronic phloridzin treatment in muscle GLUT4 knockout mice

Animal study · Male muscle-specific GLUT4 knockout mice treated from 12 to 20 weeks of age; age-matched untreated knockout and control mice [2]

Phloridzin prevented sustained elevation of basal glucose and preserved hepatic insulin responsiveness, while substantial deficits in whole-body and skeletal-muscle insulin-stimulated glucose uptake remained. Adipose responses differed by tissue.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Basal plasma glucose at 20 weeksConcentration 7.0 ± 0.7 mM (PHZ-treated knockout) vs. 7.0 ± 0.3 mM (control); P > 0.05[2]
Insulin-stimulated whole-body and gastrocnemius glucose uptake during clampResidual impairment versus control Whole body: 142 ± 8 vs. 224 ± 8 μmol/kg/min, P < 0.01; muscle: 49 ± 8 vs. 237 ± 12 nmol/g/min, P < 0.001 (PHZ-treated knockout vs. control; means ± SE)[2]
Hepatic suppression and adipose glucose uptake during clampTissue-specific response Hepatic glucose-production suppression not significantly different from control; white adipose: 27 ± 9 vs. 28 ± 3 nmol/g/min, P > 0.05; brown adipose: 633 ± 114 vs. 237 ± 24 nmol/g/min, P < 0.05 (PHZ-treated knockout vs. control; means ± SE)[2]

Conditions shared by the study groups

Route
Subcutaneous osmotic pump
Frequency
Chronic pump delivery
Treatment course
12–20 weeks of age
Vehicle
Saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Phloridzin-treated muscle GLUT4 knockout mice
0.7 mg/day
Untreated muscle GLUT4 knockout mice and pooled age-matched wild-type, lox/lox and cre controlsBasal glucose became comparable to control; hepatic insulin suppression was preserved, but whole-body and muscle glucose uptake remained below control. Brown adipose uptake exceeded control and white adipose uptake was not significantly different from control.[2]
Phloridzin-treated muscle GLUT4 knockout mice
Model: Male muscle GLUT4 knockout mice; treated group n = 5
Reported limits: No saline-pump sham comparator specified; hydration state and lot purity not specified.
Methods and source locations

Compound reported in the paper: Phlorizin (Phloridzin); Compound label in the paper: PHZ (phloridzin)

Male muscle-specific GLUT4 knockout mouse model; effects and residual defects are specific to this design.

Methods: Animals, surgery/treatment and clamp/flux/statistical analysis; Results: phloridzin treatment paragraph; Figures 1 and 3 with captions

Basal plasma glucose at 20 weeks: Results text values; means ± SE. Figure 1a time course viewed. PHZ group n = 5; figure caption gives 5–10 experiments across groups. — Results: phloridzin treatment paragraph; Figure 1a and caption

Insulin-stimulated whole-body and gastrocnemius glucose uptake during clamp: Hyperinsulinemic-euglycemic clamp with tracer-based flux measurements. Values from Results; Figure 1c,d checked visually. Figure captions: 5–10 experiments; treated group n = 5 in Methods. — Results: phloridzin treatment paragraph; Figure 1c,d and caption

Hepatic suppression and adipose glucose uptake during clamp: Hepatic suppression derived from tracer glucose flux; adipose uptake measured using 2-deoxyglucose tracer. Figure 3a–c viewed. Figure captions: 5–10 experiments; treated group n = 5 in Methods. — Results: phloridzin treatment paragraph; Figure 3a–c and caption

Phloridzin-treated muscle GLUT4 knockout mice · Methods: Animals and treatment surgery; Results phloridzin paragraph; Figures 1 and 3

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 60-81-1
Applications SGLT1/SGLT2 inhibitor
Formula C21H24O10
Molecular Weight 436.4
Synonyms Phlorhizin; Phlorizoside; Phloridzin
SMILES
C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 81 mg/mL (185.6 mM)
Water Insoluble
Ethanol Warmed: 8 mg/mL (18.33 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Phlorizin (Phloridzin) Research References

  1. [1] Hummel CS, Lu C, Loo DD, et al. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2 American journal of physiology. Cell physiology (2011). PMID: 20980548 DOI: 10.1152/ajpcell.00388.2010 Source material
  2. [2] Kim JK, Zisman A, Fillmore JJ, et al. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4 The Journal of clinical investigation (2001). PMID: 11435467 DOI: 10.1172/jci10294 Source material

Publications

1 publication citing this product

  1. Subramaniam M, .et al. , Am J Physiol Regul Integr Comp Physiol, 2019, Nov 20 PMID: 31746628

Added to your cart

View Cart Checkout
Loading...